Logo image of PULM

PULMATRIX INC (PULM) Stock Fundamental Analysis

NASDAQ:PULM - Nasdaq - US74584P3010 - Common Stock - Currency: USD

8.89  -0.01 (-0.11%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PULM. PULM was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for PULM as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, PULM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PULM had negative earnings in the past year.
PULM had a negative operating cash flow in the past year.
PULM had negative earnings in each of the past 5 years.
PULM had a negative operating cash flow in each of the past 5 years.
PULM Yearly Net Income VS EBIT VS OCF VS FCFPULM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

PULM has a worse Return On Assets (-151.43%) than 84.62% of its industry peers.
The Return On Equity of PULM (-170.59%) is worse than 65.64% of its industry peers.
Industry RankSector Rank
ROA -151.43%
ROE -170.59%
ROIC N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
PULM Yearly ROA, ROE, ROICPULM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PULM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PULM Yearly Profit, Operating, Gross MarginsPULM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PULM has about the same amount of shares outstanding.
Compared to 5 years ago, PULM has more shares outstanding
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PULM Yearly Shares OutstandingPULM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PULM Yearly Total Debt VS Total AssetsPULM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -33.12, we must say that PULM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -33.12, PULM is doing worse than 86.67% of the companies in the same industry.
PULM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.12
ROIC/WACCN/A
WACC10.06%
PULM Yearly LT Debt VS Equity VS FCFPULM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 8.90 indicates that PULM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.90, PULM belongs to the top of the industry, outperforming 81.03% of the companies in the same industry.
A Quick Ratio of 8.90 indicates that PULM has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 8.90, PULM belongs to the best of the industry, outperforming 81.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.9
Quick Ratio 8.9
PULM Yearly Current Assets VS Current LiabilitesPULM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

PULM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.26%.
Looking at the last year, PULM shows a very negative growth in Revenue. The Revenue has decreased by -83.55% in the last year.
The Revenue has been decreasing by -0.26% on average over the past years.
EPS 1Y (TTM)-38.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.12%
Revenue 1Y (TTM)-83.55%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PULM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.43% on average per year.
PULM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.66% yearly.
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PULM Yearly Revenue VS EstimatesPULM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PULM Yearly EPS VS EstimatesPULM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Also next year PULM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PULM Price Earnings VS Forward Price EarningsPULM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PULM Per share dataPULM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as PULM's earnings are expected to grow with 28.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.57%
EPS Next 3Y28.64%

More info and screens

0

5. Dividend

5.1 Amount

PULM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMATRIX INC

NASDAQ:PULM (6/6/2025, 8:21:20 PM)

8.89

-0.01 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2025-05-09
Earnings (Next)08-11 2025-08-11
Inst Owners9.28%
Inst Owner Change-2.42%
Ins Owners0.65%
Ins Owner Change0%
Market Cap32.45M
Analysts82.86
Price Target10.2 (14.74%)
Short Float %0.5%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.89
P/FCF N/A
P/OCF N/A
P/B 4.54
P/tB 4.54
EV/EBITDA N/A
EPS(TTM)-3.34
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.75
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0.53
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -151.43%
ROE -170.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.89%
Cap/Sales 12.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.9
Quick Ratio 8.9
Altman-Z -33.12
F-Score3
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)64.52%
Cap/Depr(5y)80.64%
Cap/Sales(3y)5.28%
Cap/Sales(5y)4.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.12%
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue 1Y (TTM)-83.55%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%
EBIT growth 1Y-3.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.95%
OCF growth 3YN/A
OCF growth 5YN/A